within Pharmacolibrary.Drugs.ATC.N;

model N05AX15
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.52,
    Cl             = 0.11 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 3 / 1000000,
    adminCount     = 1,
    Vd             = 0.016800000000000002,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0025,
    Tlag           = 15.0
  );

  annotation(Documentation(
    info ="<html><body><p>Cariprazine is an atypical antipsychotic medication primarily used for the treatment of schizophrenia and bipolar disorder in adults. It acts as a partial agonist at dopamine D2/D3 receptors, with preference for D3, as well as a partial agonist at serotonin 5-HT1A receptors. Cariprazine is approved by regulatory agencies such as the US FDA and EMA for psychiatric indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are based on adults, including both sexes, with schizophrenia or bipolar disorder receiving oral cariprazine in clinical trials. Values are typical of healthy subjects and patients, with no significant differences due to age, sex or race.</p><h4>References</h4><ol><li><p>DeBattista, C, &amp; Schatzberg, AF (2024). The Black Book of Psychotropic Dosing and Monitoring. <i>Psychopharmacology bulletin</i> 54(3) 8–59. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38993656/&quot;>https://pubmed.ncbi.nlm.nih.gov/38993656</a></p></li><li><p>Rosa, ME, et al., &amp; Kapás, M (2025). Lack of Clinically Meaningful Effect of Cariprazine on the Pharmacokinetics of a Combined Oral Contraceptive. <i>Neurology and therapy</i> 14(1) 291–301. DOI:<a href=&quot;https://doi.org/10.1007/s40120-024-00686-7&quot;>10.1007/s40120-024-00686-7</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39699744/&quot;>https://pubmed.ncbi.nlm.nih.gov/39699744</a></p></li><li><p>Yeung, PP, et al., &amp; Findling, RL (2023). Cariprazine in Pediatric Patients with Autism Spectrum Disorder: Results of a Pharmacokinetic, Safety and Tolerability Study. <i>Journal of child and adolescent psychopharmacology</i> 33(6) 232–242. DOI:<a href=&quot;https://doi.org/10.1089/cap.2022.0097&quot;>10.1089/cap.2022.0097</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37437109/&quot;>https://pubmed.ncbi.nlm.nih.gov/37437109</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N05AX15;
